

Jamna Auto Industries Ltd.

June 12, 2020

To,

BSE Limited

National Stock Exchange of India Limited

Phiroze Jeejeebhoy Towers, Dalal

Exchange Plaza, Plot no. C/1, G Block,

Street, Mumbai- 400001 Maharashtra

Bandra-Kurla Complex, Bandra (E)

Mumbai - 400 051, Maharashtra

BSE Code: 520051 NSE Code: JAMNAAUTO

<u>Subject- Newspaper Advertisement- Audited Financial Results for the quarter and year ended on March 31, 2020</u>

Dear Sir/Madam,

Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the copy of newspaper advertisement with respect to Audited Financial Results for the quarter and year ended March 31, 2020 published in Business Standard and Jansatta dated June 11, 2020.

You are requested to take the same on records.

Thanking you,

Yours Faithfully,

For Jamna Auto Industries Limited

Praveen Lakhera

Company Secretary & Head-Legal

Gilead working on combo of Remdesivir, other drugs

But India still awaits a commercial launch of the Covid-19 drug

Mumbai, 10 June

ven as India awaits the commercial launch of Remdesivir, US drug major Gilead Sciences is studying other molecules like rheumatoid arthritis drugs — Baricitinib and Tocilizumab — as combination therapies with Remdesivir.

Patient recruitment for the Tocilizumab combination therapy study will begin this month.

Meanwhile, the company said it applied for a new drug application (NDA) in India for Remdesivir in order to support the voluntary licensees based in India.

For this, Gilead recently signed non-exclusive voluntary licensing agreements to further expand supply of the drug. It could not comment on a timeline for launching the drug in the Indian market.

A Gilead spokesperson said, "The timeline to get Remdesivir to Indian patients that need it will depend on the licensees. Our individual licensees will also file applications with the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell remdesivir, while waiving the requirement for undertaking local clinical trials."

Licensees here — Cipla, Hetero Labs, Jubilant Lifesciences and Mylan — are yet to get a marketing


Company sources indicate that they are ready with the product and are awaiting clarity from the Drug Controller General of India (DCGI) on animal toxicology study requirements. The company cannot start commercial production without the product licence from the drug con-

Meanwhile, some states in India like Maharashtra that are severely affected by the virus have indicated that they are open to sourcing the drug from other countries like Bangladesh if need be at a cost of ₹12 crore for 10,000 vials, or around ₹12,000 per vial. Under World Trade Organization provisions, lesser developed countries like Bangladesh can produce generic versions of patented ugs without seeking a licence.

Even as patients here await the drug to be made available in the market, its innovator has started working on other potential combinations with the drug and expects results soon. Experts feel that this is imperative as the new coronavirus mutates fast and one has to keep looking for new drugs to combat it.

A scientist working on repurposed drugs in the department of science and technology, Government of India said that this virus is mutating quite fast.

'The drugs we are trying to use on patients to improve recovery are basically using a pathway to stop or reduce the virus from replicating inside a human cell. As the virus mutates, a drug's pathway may not work and thus it may lose efficacy. We would have to keep looking for



After Remdesivir, an antiviral drug originally developed for Ebola, came into limelight for being effective in recovery of Covid-19 cases, the US company started working on other drugs that could be used as a combination with the primary drug Remdesivir to help critically ill Covid


Covid-19 who are critically ill. We are and monitoring emerging data on evaluate Roche's tocilizumab (sold as actively exploring additional studies of Remdesivir in combination with other drugs and will share information as it becomes available."

The spokesperson also added that at this stage, however, the highest priority is the clinical development of

other drugs being explored to treat patients with Covid-19. National Institute of Allergy and Infectious Diseases will be evaluating a combination of Remdesivir and Baricitinib in an upcoming study. We will share further details on planned studies in the

Gilead has teamed up with another multinational Roche and already announced clinical collaboration to

PANACEA SURGES 20%



approach has a much higher probability than any other modern vaccine being touted, he claimed

Jain further added that it was easy to scale up in terms of production, and convenient to transport the same. The raw material will be made at the firm's Punjab facility, while the final vaccine will be made at Baddi (Himachal).

Half the 500 million doses will be made available in India. Panacea will start production of the trial batch by September. Under the collaboration,

Panacea will be responsible for product development and commercial manufacturing, with the JV undertaking clinical development and regulatory submissions globally. Both Panacea and Refana will undertake sales and distribution in their respective territories. "Wholly inactive viral vaccines have a higher probability of being safe," said Jain. The coverage of this vaccine, according to Jain, would last for several years.

Phillip Schwartz, chief scientific and medical advisor to Refana Inc, said: "Utilising proven models of viral pathogenesis and parallel conduct of multiple pre-clinical and clinical studies, Refana believes it can significantly accelerate the vaccine development."

Actemra) as a potential combination

domised, double-blind, placebo-con-

trolled Phase 3 clinical trial evaluating

the safety and efficacy of Remdesivir

plus intravenous Tocilizumab in hos-

pitalised patients with severe Covid-

19 pneumonia. The trial is being con-

As we learn more about Covid-19,

'The Remdacta study is a ran-

treatment for Covid-19.

ducted globally.'

Panacea, Refana join hands for Covid vaccine Chennai start-up to develop molecules to combat Covid

A Chennai-based incubation centre for research Bioneemtec India has joined the efforts to develop a compound which can control replication of the coronavirus in the body, thus controlling the virus. The start-up has been working on developing molecules with anti-HIV properties and as Covid-19 also has a similar activity, it started developing molecules targeting the disease. "Data from the preliminary study shows compound is active against Covid-19. We have filed for patent and are looking for funding to take the research forward. We have to develop 30-50 compounds and screen through wet lab analyses," said Magendran Balaachari, advisor, Bioneemtec India. The firm is expecting it would be able to bring the product in three years.

we know that some patients develop

acute respiratory distress syndrome

(ARDS), a severe inflammatory dis-

ease of the lungs, causing direct inj-

ury that leads to shortness of breath

whether patients with severe Covid-

19 may achieve additional benefit by

combining Remdesivir with Tociliz-

umab to inhibit these inflammatory

"This study aims to determine

and rapid breathing.

patients. The spokesperson said, "We Remdesivir together with ongoing in near future," the person said. recognise that combination theravitro screening of other antivirals pies may be required to further imagainst the virus that causes Covid-19. "While we are studying Remdesivir prove outcomes for patients with

J&J to start human trials of vaccine in July

on Wednesday it would bring ugh 2021, even before it has eviforward by two months human trials of its potential Covid-19 vaccine to the second half of cines for Covid. J&J's study will July, as the drugmaker rushes to develop a shot for the contagious respiratory disease.

The firm has already signed deals with the US government to create enough manufacturing The trial will take place in the capacity to produce more than 1 United States and Belgium.

Hero MotoCorp has pared its

capital expenditure for the cur-

rent fiscal (financial year 2020-

SHALLY SETH MOHILE

Mumbai, 10 June

Johnson & Johnson (J&J) said billion doses of its vaccine throdence that it works. There are no approved treatments or vactest the vaccine against a placebo and assess its safety and immune response in 1,045 healthy people aged 18 to 55 years, as well as those 65 years and older.



"Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have

the clinical development," said J&J's Chief Scientific Officer Paul Stoffels.

The company is also in talks with the National Institutes of Allergy and Infectious Diseases to start larger, late-stage trials ahead of schedule, depending on results of the early studies and regulatory approval.

Moderna Inc is at the fore-

been able to further accelerate front of Covid vaccine development and has started testing its candidate in a mid-stage trial that will enroll 600 patients. The firm expects to begin late-stage trials in July. Moderna's vaccine uses messenger RNA technology, an approach that has not yet been approved for any medicine, while J&J is utilising the same technology used to make its Ebola shot.

"We chose this over others



MAGMA HOUSING FINANCE

MAGMA HOUSING FINANCE LIMITED

Registered Office: Development House, 24 Park street, Kolkata-700 016 CIN: U65922WB2004PLC229849; Website: https://www.magmahfc.co.in

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 31 MARCH 2020

[Regulation 52 (8), read with Regulation 52 (4), of the SEBI (LODR) Regulations, 2015]

Half Year Ended Year Ended

31 March 31 March 31 March 31 March **Particulars** (Unaudited Unaudited) (Audited) (Audited) Total Income from operations 18,621.52 13,404.64 35,636.65 24,551.38 2,359.84 5,428.56 Profit from ordinary activities before tax 2,067.60 4,700.28 1,868.74 1,638.29 4,264.84 3,401.51 Net Profit from ordinary activities after tax 2.750.65 [comprising profit / (loss) for the period (after tax and Other Comprehensive Income (after tax)] 16,582.99 14,810.25 16,582.99 14,810.25 Paid up Equity Share Capital 10,580.13 767.01 31,475.45 19,275.75 Reserves (excluding Revaluation Reserve) 27,163.12 Net worth 15,577.26 48.058.44 34,086.00 ,98,279.42 38,340.06 Paid up Debt Capital / Outstanding Debt ,38,340.06 ,98,279.42 Outstanding Redeemable Preference shares Debt Equity Ratio 4.13 4.06 4.06 Earnings Per Share a. Basic 2.30 (in ₹) 1.08 b. Diluted (in ₹) 1.23 2.27 Capital Redemption Reserve Debenture Redemption Reserve Debt Service Coverage Ratio

The above is an extract of the detailed format of half yearly and annual financial results filed with the Stoc Exchanges under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations 2015. The full format of the half yearly and annual financial results are available on the website of the Stoci Exchange (www.bseindia.com) and the Company (www.magmahfc.co.in).

For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52 (4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchange (www.bseindia.com) and the Company (www.magmahfc.co.in).

For Magma Housing Finance Limited

Place : Mumbai Dated : 09 June 2020

Manish Jaiswal

Managing Director & Chief Executive Officer DIN: 07859441

21, or FY21) to ₹600 crore as the market leader seeks to cut costs and conserve cash amid the pandemic, the company's management said in an investor call on Wednesday. The capex reduction will be struck, in the current month.

applicable in all areas includdevelopment, the firm said. "Earlier, our projected capex for the current year was ₹1,000 crore. We have rationalised it to ₹600 crore for the current year," said Niranjan Gupta, chief financial officer at Hero MotoCorp.

Touching upon the demand scenario after easing of the lockdown, officials said the retail uptick has been very encouraging and Hero hopes to clock 80



Hero MotoCorp cuts capex

per cent (volume) of what it was doing before the pandemic

ovation, except for research and a monthly run rate of 500,000-550,000 units before Covid-19, said Naveen Chauhan, head of sales and after-sales at Hero. Around 90 per cent of the company's dealer outlets have resumed operations, he said.

On Tuesday, the firm posted a decline of 15 per cent in its standalone net profit for the March quarter (Q4FY20) compared to SI1 a year ago. Missing the Street Volume woes indicate a bumpy estimates, it fell to ₹621 crore in

Q4FY20 as against ₹730.32 crore in the year-ago period.

The company's management stopped short of any quarterly or full year guidance on volumes even as they said the ramp up of demand and supply had been more than satisfactory. Citing good crop output, and the prediction of normal monsoon Hero expects the rural economy to fare better than the urban. The region accounts for one in This should be cut around every two motorcycles sold by the firm. "It is early days to pre dict a trend, we will have to watch as we move forward," said Chauhan. Hero MotoCorp has potential growth tailwinds in the second half of FY21 from rural recovery and downtrading in motorcycles, said ICICI Securities in a research note on Wednesday.

ride for Hero MotoCorp

[Pursuant to Rule 30 of The Companies (Incorporation) Rules, 2014] **BEFORE THE CENTRAL GOVERNMENT** THE REGIONAL DIRECTOR, NORTHERN REGION

MINISTRY OF CORPORATE AFFAIRS, NEW DELHI In the matter of The Companies Act, 2013, Section 13 (4) of The Companies Act, 2013 and clause (a) of sub-rule (5) of Rule 30 of The Companies (Incorporation) Rules, 2014

INC - 26

In the matter of Shree Labh Lakshmi Capital Services Private Limited ("the Company") having its registered office at 303, Himland House, D5 Karampura Commercial Complex, New Delhi - 110 015

Notice is hereby given to the General Public that the Company proposes to make application to the Central Government under Section 13 of The Companies Act, 2013 seeking confirmation of alteration of Memorandum o Association of the Company in terms of Special Resolution passed at the Extra Ordinary General Meeting held on Friday the 20th day of March, 2020 to enable the Company to change its Registered office from NCT of Delhi to "State of Punjab". Any person whose interest is likely to be affected by the proposed change of

he registered office of the Company may deliver either on the MCA-21 portal (www.mca.gov.in) by filing investor complaint form or cause to be delivered or send by registered post of his/her objections supported by ar affidavit stating the nature of his/her interest and grounds of opposition to The Regional Director, Northern Region, Ministry of Corporate Affairs, New Delhi at the address B-2 Wing, 2nd Floor, Pt. Deendayal Antyoday Bhawan CGO Complex, New Delhi - 110 003 within 14 (Fourteen) days of the date of publication of this notice with a copy of the same to the Applicant Compan at its Registered Office at the address mentioned below: Regd. office Address: 303, Himland House, D5, Karampura Commercia

Complex, New Delhi - 110 015. For and on behalf of the Applicant Shree Labh Lakshmi Capital Services Private Limited

Sachin Kumar Gard Date: 08.06.2020 Director DIN: 05106926

Place: New Delhi

JAMNA AUTO INDUSTRIES LIMITED

Regd. Office: Jai Springs Road, Industrial Area, Yamuna Nagar - 135001, Haryana Phone & Fax: 01732-251810/11/14 email: praveen@jaispring.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

S.	Particulars		Quarter ende	Year ended		
No.	Tartibulato	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
1 2	Total Income from operations Net Profit/ (Loss) for the period	23,749.43	22,858.99	54,283.50	112,895.15	213,481.23
3	(before tax, exceptional items) Net Profit/ (Loss) for the period before tax	1,966.13	1,342.60	5,356.58	7,164.12	21,549.78
	(after exceptional items) Net Profit/ (Loss) for the period after tax	1,966.13	1,342.60	5,356.58	7,164.12	21,549.78
	(after exceptional items)	1,103.28	1,007.47	3,336.67	4,787.97	13,745.13
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,124.57	1.014.22	3.190.36	4.797.02	13,607.86
6 7	Equity Share Capital Reserves (excluding Revaluation Reserve)	3,983.25 47,687.27	3,983.23 47,619.07	3,983.19 46,971.75	3,983.25 47,687.27	3,983.19 46,971.75
8	Earnings Per Share (of Rs. 1/- each) (not annualised) (In Rs.) Basic: Diluted:	0.28 0.28	0.25 0.25	0.84 0.84	1.20 1.20	3.45 3.45

Notes:

Date: June 10, 2020

The above is an extract of the detailed format of Quarterly/Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Yearly Financial Results are available on the Stock Exchanges websites viz. www.bseindia.com and www.nseindia.com and website of the Company at

The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on June 10, 2020

Information of standalone financial results in terms of the Listing Regulations is as under

(Rs. in Lakhs unless otherwise stated) Quarter ended **Particulars** 31.03.2020 31.12.2019 31.03.2020 31.03.2019 31.03.2019 Revenue from operations 21,055.26 21,524.46 47,287.96 105,882.11 204,553.11 20.332.32 1.788.68 1.307.71 4.601.60 6.855.49 Profit before tax Total Comprehensive income for the period 1,117.91 1,079.14 3.050.67 4,806.51 13,839.80

For Jamna Auto Industries Ltd. (P . S Jauhar) Managing Director & CEO

Tata Steel Dutch workers strike work on job cuts

ISHITA AYAN DUTT Kolkata, 10 June

Ore preparation workers at Tata Steel's Dutch operations went on strike on Wednesday demanding protection from job cuts. "It is the first time in 28 years that people at Tata Steel IJmuiden are on strike," a spokesperson of Dutch labour union FNV said.

The workers are striking at a time when the steel industry is facing headwinds with major customers shut. The union wants, among other things, the guarantee that there will be no redundancies.

The union wants agreements in the Employment Pact be extended till 2026. FNV said that the employees do not want Tata Steel Netherlands and Tata Steel UK to be combined.

Tata Steel said: "Industrial action will put further pressure and it is important all stakeholders make every effort to keep the company in good health." Tata Steel Europe has two steelmaking hubs: Ijmuiden, and Port Talbot, Wales.

According to the union, it was unlikely work would be laid down after the management did not respond to their demands. However, Tata Steel said: "We have invited FNV for talks and, while it has not responded, our door is still open."

POST BOX NO. 10077 TEL. NOS.: +91 22 22197101 FAX :0091-22- 2207 1612 / 6772 Email: writetous@bbtcl.com Website: www.bbtcl.com CIN: L99999MH1863PLC000002

confirmation in accordance with the applicable procedure

Date: 10th June, 2020



THE BOMBAY BURMAH TRADING CORPORATION, LIMITED

NOTICE (for attention of Equity Shareholders of the Corporation)
Transfer of Equity shares of the Corporation to Investor Education and Protection Fund (IEPF) Authority

This Notice is published in terms of Section 124(6) of the Companies Act, 2013 ("the Act") read with the Investor Education and Protection Fund (IEPF) Authority (Accounting Audit, Transfer and Refund) Rules, 2016 (as amended from time to time) (The Rules'). The Act and Rules, amongst other matters, contain provisions for transfer of unclaimed dividend to IEPF and transfer of shares in respect of which dividend remains unclaimed for seven consecutive years or more to the IEPF Authority. Accordingly, the unclaimed dividend and the corresponding shares in respect of which dividend has not been claimed for a period of seven consecutive years i.e the dividend declared for FY 2012-13 8

onwards shall be transferred to IEPF Authority during FY 2020-21. Notice is further given that in view of the unprecedented circumstances caused by Covid-19 pandemic, serving physical notices in this regard to the shareholders whose emai ds are not registered with the Depository/ Registrar and Share Transfer Agent ('RTA'), is difficult. Therefore, this newspaper notice shall be considered as individual notice to such shareholders in compliance with IEPF Rules. However, for the benefit of such Shareholders, efforts will be made to send out individual communication upon restoration of complete normalcy and considering the feasibility of sending out physical notices in accordance with the guidelines of the government under the Epidemic Diseases Act 1897. For the convenience of the Shareholders, the Corporation has also uploaded the application cum undertaking on its website i.e. www.bbtcl.com. Notice by email is being sent to the shareholders whose emails IDs are registered with the Depository/ Registrar and Transfer Agents, as on date.

Further, the Corporation also requests the Shareholders whose email ids are not registered to make an application for registering the same with the Corporation/ RTA o with their individual depositories if holding the shares in demat form. The application for registering the enail ID should be accompanied with the following details and sen to the Corporation at writetous@bbtcl.com or investorservices@bbtcl.com and RTA at einward.ris@kfintech.com. The registration of email ID is subject to verification and

) Name of the shareholder(s); ii) Number of shares held; iii) Folio No/ DP id/ Client id; iv) Pan No & Aadhar No; v) Contact details & vi) Email id: Upon registration of email ids all future communications shall be made electronically to such shareholders

The concerned shareholders are requested to take necessary actions on or before 5th September, 2020, failing which the Corporation shall, with a view to comply with the requirements set out in the Rules, transfer the said unclaimed dividend along with the corresponding shares to IEPF Authority by way of corporate action. The name of the concerned shareholders and their folio numbers or DP ID/ Client ID numbers are available on the Corporation's website i.e. www.bbtcl.com The concerned shareholders, holding shares in physical form and whose shares are liable to be transferred to IEPF Authority, may note that the Corporation would be issuin

tuplicate share certificate(s) in lieu of the original share certificate(s) held by them for the purpose of dematerialisation and transfer of shares to IEPF Authority as per the Rules

and upon such issue, the original certificate(s) which stands registered in their name will stand automatically cancelled and be deemed non-negotiable. The shareholder may further note that the details uploaded by the Corporation on its website should be regarded as and shall be deemed to be adequate notice in respect of issue of such certificate(s) by the Corporation for the purpose of transfer of shares to IEPF Authority pursuant to the Rules. If the shares are held in demat form, the Corporation shall inform depository by way of a Corporate Action for transfer of shares lying in the demat account in favour of IEPF. Please note that no claim shall lie against the Corporation in respect of the unclaimed dividend amount and shares transferred to IEPF. Shareholders may note that both the unclaimed dividend amount transferred to IEPF and the shares transferred to the Demat Account of the IEPF Authority including all benefits accruing on such shares, if any,

can be claimed back from the IEPF Authority by the shareholders by submitting an online application in the prescribed Form IEPF-5 available on the website www.iepf.gov.ii and sending a physical copy of the same duly signed to the Corporation along with requisite documents enumerated in the Form IEPF-5. For any information/clarifications on this matter, the concerned shareholders may write to the Corporation at investorservices@bbtcl.com or contact its Registrar and Share Transfer Agent – Kfin Technologies Private Limited, Selenium Building, Tower B, Plot No. 31 & 32, Financial District, Nanakramguda, Hyderabad, Telangana-500 032

> For The Bombay Burmah Trading Corporation, Limited Sanjay Kumar Chowdhary

Company Secretary & Compliance Office

जनसत्ता, नई दिल्ली, 11 जुन, 2020





न्युनतम- 28.4 डि.से.

सूर्यास्त- 19:19

विदेशों से आए यात्रियों से दिल्ली और मुंबई में फैला संक्रमण: जैन

जनसत्ता संवाददाता नई दिल्ली, 10 जून।

बुधवार को स्वास्थ्य मंत्री सतेंद्र जैन ने कहा कि कोरोना संक्रमण की बीमारी पहले हमारे देश में नहीं थी। यह विदेशों से आई है। दिल्ली और मुम्बई में विदेश से विमान में यात्री लाए गए थे। हमने उस दौरान विरोध भी दर्ज किया था कि विदेशों से इतने लोगों को ला रहे हैं, तो यह बीमारी फैल सकती है। लेकिन केंद्र सरकार ने नहीं माना। इसी वजह से दिल्ली और मुम्बई में सबसे अधिक केस हैं। बाकी जगहों पर विदेश से यह यात्री नहीं आए थे, इसलिए वहां पर बीमारी अधिक नहीं फैली है।

स्वास्थ्य मंत्री सतेंद्र जैन ने कहा कि मानव इतिहास में यह सबसे बड़ा संकट है। आज से 100 साल पहले स्पैनिस फ्लू नाम से महामारी आई थी, जो इतने बड़े स्तर पर पूरी दुनिया में

अस्पताल के बाहर

एलईडी बोर्ड से

मिलेगी बिस्तर

उपलब्धता की

जानकारी

नर्ड दिल्ली। दिल्ली के

अस्पतालों के बाहर ही अब

मरीजों को अस्पताल में बिस्तर

उपलब्धता की जानकारी मिल

जाएगी। बुधवार को उपराज्यपाल

ने सभी अस्पतालों को एलईडी

बोर्ड की व्यवस्था करने और उस

पर सभी जानकारी देने के आदेश

दिए है। इससे अस्पताल जाने

वाले मरीजों को राहत होगी और

जगह होने पर भी कोई अस्पताल

मरीज को भर्ती करने से इनकार

स्वास्थ्य सुविधाओं की पारदर्शिता में सुधार और जनता को सुविधा प्रदान करने के लिए यह

पहल की गई है। आदेशों के मुताबिक सभी प्रमुख अस्पताल/ क्लीनिक/ नर्सिंग होम अपने

परिसर के बाहर प्रवेश द्वार पर एलईडी बोर्ड पर बिस्तर की उपलब्धता (कोविड व नॉन कोविड दोनों के संदर्भ में), बिस्तर/कमरों के लिए फीस एवं

एडमीशन के लिए संबंधित व्यक्ति

का विवरण साफ–साफ अक्षरों में

(जसं)

प्रदर्शित करेंगे।

नहीं कर सकेगा।

फैला था। यह 100 साल के बाद सबसे बड़ी त्रासदी है। उन्होंने कहा कि हमें सामुदायिक संक्रमण के झगड़े में नहीं पडना है। उसके बारे में फैसला केंद्र सरकार ही करेगी। शुरू में जब केस एक या दो होता था, तब एक मामले पर 600 लोगों तक की जांच की

नई दिल्ली

रिडिसिं

आज जब 1500 मामले हैं तो आज यह करीब 9 लाख लोग हो जाते हैं और इतनी जांच संभव ही नहीं है। उन्होंने बताया कि एम्स निदेशक ने भी कहा था कि सील क्षेत्र के अंदर सामुदायिक संक्रमण है। बाकी जगह संक्रमण है या नहीं, यह केंद्र सरकार ही बताएगी। उन्होंने कहा अब हर 14 दिन में हमारे मामले दोगुने हो रहे हैं, तो साफ है कि अगले 14 दिन में मामले दोगुने होंगे।

अस्पतालों में खाली हैं 4000 बिस्तर सत्येंद्र जैन ने बताया कि दिल्ली में अभी यह विषाणु एक या डेढ़ महीने में खत्म हो सकता हैं।

31309 मामले हैं। 09 जून को 1166 मामले आए थे। इस समय दिल्ली में 18543 सिक्रय मामले हैं। अभी अस्पताल में करीब 5 हजार लोग भर्ती हैं और कुल बिस्तर में से अभी 4 हजार खाली हैं।

कल निजी अस्पताल में 2 हजार बिस्तर बढाएं हैं। दो-तीन दिन के अंदर यह सभी बिस्तर तैयार हो जाएंगे। यह बीमारी बहुत तेजी से फैलती है। यदि कोई व्यक्ति कोरोना से संक्रमित हो जाता है, तो उसे ठीक होने में करीब दो सप्ताह लग जाते हैं। ठीक होने से पहले वह दो से चार लोगों को संक्रमित करता है। इसी वजह से मामले बढ रहे हैं। 30 जुन तक के पूर्वानुमान पर स्टेडियम, बैंक्वेट हॉल और होटल भी तैयारी की जा रही है।

अब कोरोना के साथ जीना सीखना होगा उन्होंने कहा कि पहले हमें लगता था कि जाएगा। लोगों को लगता था कि गर्मी बढेगी.

तब यह विषाण् खत्म हो जाएगा। लोगों मानना था कि 30 डिग्री तक तापमान पहुंचेगा, तो खत्म हो जाएगा, लेकिन 47 डिग्री तक तापमान चला गया, विषाणु अभी भी है। अब हमें कोरोना के साथ सीखना होगा। यह अभी

दो या तीन साल

कोरोना के साथ ही जीना सीखना होगा अब : सतेंद्र जैन

Phone & Fax: 01732-251810/11/14 email: praveen@iaispring.com

FED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020 (Rs. in Lakhs unless otherwise stated)

	(NS. III Eakiis diliess otherwise states								
S.	Destinutore		Quarter ende	Year ended					
No.	Particulars	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019			
$\neg \neg$	Total Income from operations	23,749.43	22,858.99	54,283.50	112,895.15	213,481.23			
2	Net Profit/ (Loss) for the period								
	(before tax, exceptional items)	1,966.13	1,342.60	5,356.58	7,164.12	21,549.78			
3	Net Profit/ (Loss) for the period before tax								
	(after exceptional items)	1,966.13	1,342.60	5,356.58	7,164.12	21,549.78			
4	Net Profit/ (Loss) for the period after tax								
ا ہ	(after exceptional items)	1,103.28	1,007.47	3,336.67	4,787.97	13,745.13			
5	Total Comprehensive Income for the period								
	[Comprising Profit / (Loss) for the period (after tax) and	4 404 57	4 044 00	0.400.00	4 707 00	40.007.00			
ا ہ	Other Comprehensive Income (after tax)]	1,124.57	1,014.22	3,190.36	4,797.02	13,607.86			
6	Equity Share Capital	3,983.25	3,983.23	3,983.19		3,983.19			
/	Reserves (excluding Revaluation Reserve)	47,687.27	47,619.07	46,971.75	47,687.27	46,971.75			
8	Earnings Per Share (of Rs. 1/- each) (not annualised)								
	(In Rs.)	0.00	0.05	0.04	4.00	2.45			
	Basic:	0.28	0.25	0.84	1.20	3.45			
	Diluted:	0.28	0.25	0.84	1.20	3.45			
lotes:									

The above is an extract of the detailed format of Quarterly/Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Yearly Financial Results are available on the Stock Exchanges websites viz. www.bseindia.com and www.nseindia.com and website of the Company a

The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings

Information of standalone financial results in terms of the Listing Regulations is as under:

(Rs. in Lakhs unless otherwise stated)

S.	Particulars		Quarter ende	Year ended		
No.	Fatuculars	31.03.2020	31.12.2019	31.03.2019	31.03.2020	31.03.2019
1	Revenue from operations	21,055.26	21,524.46	47,287.96	105,882.11	204,553.11
2	Profit before tax	1,788.68	1,307.71	4,601.60	6,855.49	20,332.32
3	Total Comprehensive income for the period	1,117.91	1,079.14	3,050.67	4,806.51	13,839.80

For Jamna Auto Industries Ltd. (P. S Jauhar) **Managing Director & CEO**

DIN 00744518

मुख्यमंत्री दूसरे राज्यों के मरीजों का आंकडा बताएं: भाजपा

जनसत्ता सवाददाता नई दिल्ली, 10 जून।

मुख्यमंत्री अरविंद केजरीवाल देश के विभिन्न राज्यों के मरीजों का सही आंकडा जारी करें। यह मांग भाजपा प्रदेश अध्यक्ष आदेश गृप्ता ने मुख्यमंत्री में इलाज किया है, इनमें कितने मरीज डालने की कोशिश करती रही है। बाद कराने की कोई संभावना ही नहीं है।

हरियाणा, राजस्थान, पंजाब, उत्तर प्रदेश, में जनता को गुमराह करने के लिए बिहार एवं अन्य राज्यों से थे।

आदेश गुप्ता ने कहा कि मार्च में जब कोरोना का संक्रमण शुरू हुआ था। उस समय सरकार का दावा था कि दिल्ली में 30 हजार रोगी बिस्तर उपलब्ध है। लेकिन जब मई के मध्य में कोरोना के अस्पतालों पर अन्य राज्यों के को पत्र लिखकर की है। उन्होंने कहा कि 🛮 संक्रमण फैला तो चार हजार बिस्तर भी 🔻 मरीजों का बोझ है। इस दौरान सभी 📗 📗 सरकार बताए कि 10 जून तक कितने नहीं थे। इस दौरान सरकार अपनी सीमा सील होने के कारण बाहर के कोरोना के मरीजों का सरकारी अस्पतालों जिम्मेदारी को निजी अस्पतालों में मरीजों के दिल्ली में आकर इलाज

घोषणा की कि दिल्ली में बाहर वालों का इलाज नहीं होगा और सभी रोगी बिस्तर दिल्लीवालों के लिए आरक्षित रहेंगे। ऐसा कहकर सरकार ने भ्रम फैलाने की कोशिश की कि मानो दिल्ली

कार्यालय अधीक्षक राजकीय शिशु गृह, बाल अधिकारिता विभाग

क्र. सं.	संस्था द्वारा दिया गया नाम	लिंग	आयु	प्राप्ति का स्थान	प्रवेश माध्यम
1.	राधिका	F	2 माह लगभग	जे.के. लॉन, अस्पताल, जयपुर में प्राप्त	बाल कल्याण समिति, जयपुर
2.	प्रिया	F	2 माह लगभग	थाना सुभाष चौक जयपुर से प्राप्त	बाल कल्याण समिति, जयपुर

आपत्ति हो तो क्र.सं. 01 से 02 के लिए 20 दिवस के भीतर निम्न हस्ताक्षरकर्ता से सम्पर्क करें। अधीक्षक शिशु गृह, बाल अधिकारिता विभाग

गाईबीसी, 2016 के तहत ई-नीलामी बिक्री सूचना आईबीसी, 2016 के तहत बिक्री सुचना मैसर्स एक्सक्लूसिव फाइबर्स लिमिटेड

सीआईएन : U74999DL2004PLC125846 | पंजीकृत कार्यालय : 31/3203, बीडनपुरा, करोल बाग, नई दिल्ली-110005 परिसमापक का कार्यालय : खण्डेलवाल जैन एण्ड कं., जी-8 एवं 9, हंस भवन 1, बहादुर शाह जफर मार्ग, नई दिल्ली-110002 **| सी.बी. (आईबी**)-1650(**एनडी**)/2018 में आदेश सं. **सी.ए.** 83/**सी-II/एनडी**/2020 **दिनांक** 07.01.2020 के माध्यम से माननीय राष्ट्रीय कम्पनी विधि अधिकरण, नई

दिल्ली पीठ द्वारा नियुक्त परिसमापक द्वारा परिसमापन सम्पदा का भाग निर्मित करने वाले **मैसर्स एक्सक्लुसिव फाइबर्स लिमिटेड (परिसमापनाधीन)** की आस्तियों की बिक्री।

बिक्री ई-नीलामी प्लेटफॉर्म https://ncltauction.auctiontiqer.net के माध्यम से अधोहस्ताक्षरी द्वारा की जायेगी।

विवरण	ई-नीलामी की तिथि एवं समय	आरक्षित मूल्य (रु.)	ईएमडी राशि तथा दस्तावेज जमा करने की अन्तिम तिथि	संविदा वृद्धि राशि
		बैच : I		
लॉट 1 : जारी कंसर्न के रूप में कॉर्पोरेट देनदार की बिक्री	शुक्रवार, 10 जुलाई, 2020 समय : 11.30 बजे प्रातः से 1.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 19,30,00,000/- (रुपये उन्नीस करोड़ तीस लाख मात्र)	रु. 1,93,00,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 5,00,000
		बैच : II		
लॉट 2 : वाहन छोड़कर किन्तु फर्नीचर एवं फिक्सचर, कार्यालय उपकरण एवं विद्युतीय संस्थापन सहित प्लांट तथा मशीनरी, डी-2/ई-16, दहेज इंडस्ट्रियल एस्टेट, भरूच, गुजरात-392130 पर स्थित	शुक्रवार, 10 जुलाई, 2020 समय : 2.30 बजे अप. से 3.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 6,80,00,000/- (रुपये छः करोड़ अस्सी लाख मात्र)	रु68,00,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 2,00,000
लॉट 3 : अचल सम्पत्तियाँ अर्थात डी-2/ई-16, दहेज इंडस्ट्रियल एस्टेट, भरूच, गुजरात पर स्थित फैक्ट्री भूमि तथा भवन (भूमि : 54,457.96 वर्ग मीटर)। कवर्ड बिल्ट- अप क्षेत्रफल : 87160.43 वर्ग फीट	शुक्रवार, 10 जुलाई, 2020 समय : 3.30 बजे अप. से 4.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 10,80,00,000/- (रुपये दस करोड़ अस्सी लाख मात्र)	रु. 1,08,00,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 2,00,000
लॉट 4 : अचल सम्पत्तियां अर्थात प्लॉट सं. ए-51 तथा 52, ग्राम : अटाली, तालुका : वाग्रा, जिला : भरूच, गुजरात पर स्थित आवासीय रिक्त भूमि (भूमि 3,913.32 वर्ग मीटर)	शुक्रवार, 10 जुलाई, 2020 समय : 3.30 बजे अप. से 4.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 50,00,000/- (रुपये पचास लाख मात्र)	रु. 5,00,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 2,00,000
लॉट 5 : कॉर्पोरेट देनदार के वाहन-दो पहिया, बजाज डिस्कवर 150 सीसी, किमी रन : 12000 किमी, पंजीकरण तिथि : अक्टूबर 2014, पंजीकरण प्राधिकरण : भरूच, गुजरात	शुक्रवार, 10 जुलाई, 2020 समय : 4.30 बजे अप. से 5.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 21,000/- (रुपये इक्कीस हजार मात्र)	रु. 2,100/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 1,000
लॉट 6 : कॉर्पोरेट देनदार के वाहन-गुड्स कैरियर- महिन्द्रा, बोलेरो, किमी रन : 57,036 किमी, पंजीकरण तिथि : मार्च 2015, पंजीकरण प्राधिकरण : भरूच, गुजरात	शुक्रवार, 10 जुलाई, 2020 समय : 4.30 बजे अप. से 5.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 2,00,000/- (रुपये दो लाख मात्र)	रु. 20,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 10,000
लॉट 7 : कॉर्पोरेट देनदार के वाहन-ट्रैवलर बस, फोर्स मोटर्स, किमी रन : 72,000 किमी, पंजीकरण तिथि : अप्रैल 2015, पंजीकरण प्राधिकरण : भरूच, गुजरात	शुक्रवार, 10 जुलाई, 2020 समय : 4.30 बजे अप. से 5.30 बजे अप. (प्रत्येक 5 मिनट के असीमित विस्तार सहित)	रु. 4,00,000/- (रुपये चार लाख मात्र)	रु. 40,000/- 08 जुलाई, 2020 तक या इससे पूर्व 5 बजे अप. से पूर्व	₹. 20,000
लॉट 8 :	शुक्रवार, 10 जुलाई, 2020	रु. 4,00,000/- (रुपये चार	₹. 40,000/-	रु. 20,000

निरीक्षण की तिथि : 1 जुलाई, 2020 से 6 जुलाई, 2020 (12.00 बजे अप. से 4.00 बजे अप. तक) परिसमापक को पूर्व में सूचित करके।

समय : 4.30 बजे अप. से 5.30 लाख मात्र)

(प्रत्येक 5 मिनट के असीमित

विस्तार सहित)

ईओआई जमा करने की अन्तिम तिथि : 8 जुलाई, 2020 बिक्री के नियम एवं शर्तें निम्नलिखित हैं

कॉर्पोरेट देनदार के वाहन-हुंडई क्रेटा,

किमी रन : 90289 किमी, पंजीकरण

तिथि : नवम्बर 2016, पंजीकरण

प्राधिकरण : दक्षिणी दिल्ली

तिथि : 11/06/2020

स्थान : नई दिल्ली

- 1. ई-नीलामी अनुमोदित सेवा प्रदाता मैसर्स ई-प्रोक्योरमेंट टेक्नोलॉजीज लिमिटेड (https://ndtauction.auctiontiger.net) के माध्यम से बिना किसी वारंटी तथा इंडेम्निटी होने के कारण ''जहाँ है जैसे है'', ''जो है यही है'', ''जो कुछ भी है वही है आधार'' तथा ''उपचार रहित आधार'' पर संचालित की जायेगी। नीलामी 2 बैच में होगी, कॉर्पोरेट देनदार की बिक्री बैच-I के लॉट 1 में जारी कंसन के रूप में बेची जायेगी और यदि बैच-1 हेतु कोई संविदाकार नहीं होता है, व्यक्तिगत रूप से आस्तियों की बिक्री हेतु बैच-II के लॉट 2, 3, 4, 5, 6, 7 तथा 8 की ई-नीलामी संचालित की जायेगी।
- संविदाएँ निर्धारित प्रारूप में परिसमापक के पास (ऑनलाइन या हार्ड कॉपी) जमा की जायेंगी। सम्पूर्ण ई-नीलामी प्रक्रिया के विस्तृत नियम एवं शर्तों सहित संविदा प्रपत्र वेबसाइट https://ncltauction.auctiontiger.net से डाउनलोड किये जा सकते हैं।

आकाश सिंघल, परिसमापक आईबीबीआई पंजी. सं. : IBBI/IPA-001/IP-N00137/2017-18/10279

दूरभाष : +91-9868145676, ई-मेल : akash@kjco.net, exclusivefibers.cirp@gmail.com

08 जुलाई, 2020 तक या इससे पूर्व

5 बजे अप. से पूर्व

अब आ गया है यर यर

Date: June 10, 2020

Place: New Delhi



STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

	PARTICULARS	STANDALONE				(Rupees in Crores			
S. NO.		QUARTER ENDED MARCH 31, 2020 AUDITED	QUARTER ENDED MARCH 31, 2019 AUDITED	YEAR ENDED MARCH 31, 2020 AUDITED	YEAR ENDED MARCH 31, 2019 AUDITED	QUARTER ENDED MARCH 31, 2020 AUDITED	QUARTER ENDED MARCH 31, 2019 UNAUDITED	YEAR ENDED MARCH 31, 2020 AUDITED	YEAR ENDED MARCH 31, 2019 AUDITED
1.	Total Income	6,407.86	8,049.18	29,614.43	34,341.79	6,490.92	8,120.73	29,985.88	34,658.96
2.	Net Profit for the period before tax (before exceptional items/)	650.59	1,081.12	3,896.32	5,010.73	637.53	1,137.49	3,933.71	5,104.30
3.	Net Profit for the period before tax (after exceptional items*)	650.59	1,081.12	4,573.69	5,010.73	637.53	1,137.49	4,611.08	5,104.30
4.	Net Profit for the period after tax (after exceptional items*)	620.71	730.32	3,633.26	3,384.87	613.81	786.61	3,659.41	3,466.35
5.	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and other Comprehensive Income (after tax))	616.02	722.05	3,601.48	3,367.06	616.42	776.23	3,641.12	3,451.37
6.	Equity Share Capital (face value ₹2/- per share)	39.95	39.95	39.95	39.95	39.95	39.95	39.95	39.95
7.	Reserves (excluding Revaluation Reserve)			14,096.45	12,817.17	-	-	14,366.33	13,080.46
8.	Earnings per share on net profit after tax - face value Rs. 2/- each (In Rupees) a) Basic b) Diluted	31.08 31.08	36.57 36.57	181.91 181.91	169.48 169.47	30.27 30.27	39.40 39.40	182.15 182.15	172.45 172.44

"Refer note 2 and note 3 for exceptional items

- The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Company's website www.heromotocorp.com and also on stock exchange websites, www.bseindia.com and
- 2. During the year ended March 31, 2020, the Company had introduced a voluntary retirement scheme (VRS) and the Company had considered a provision of Rs. 60.11 crores for employees who have accepted to be part of VRS as exceptional item in the financial results. 3. The Company had deposited and created provision for "National Calamity contingent Duty" ('NCCD') including applicable cess in its Haridwar plant during prior years, while contesting the same
- on the ground that NCCD is in nature of excise duty and should be covered by Area based exemption. Pursuant to favourable order from Hon'ble supreme court, the provision of Rs. 737.48 has been reversed as exceptional item during the year ended March 31, 2020. 4. The Board at its meeting held on June 09, 2020 considered and recommended a final dividend @ 1250% i.e. Rs.25 per equity share of Rs. 2.00 each for the financial year 2019-20. This dividend
- together with the Interim dividend @ 3250% i.e. Rs. 65 per equity share of Rs. 2.00 each already paid to the members would aggregate to @ 4500%. Based on the guiding principles given in Ind AS-108 on 'Operating Segments', the Company's business activity fall within a single operating segment, namely automotive segment. Accordingly,

the disclosure requirements of Ind AS 108 are not applicable. 6. The above results for the quarter and year ended March 31, 2020 have been reviewed and recommended by the Audit Committee meeting held on June 9, 2020 and approved by the Board of Directors in their meeting held on June 9, 2020.

> For and on behalf of the Board of Directors PAWAN MUNJAL Chairman, Managing Director & CEO

DIN: 00004223 New Delhi, 09/06/20 Regd. office :- The Grand Plaza, Plot No.2, Nelson Mandela Road, Vasant Kunj- Phase-II, New Delhi- 110070 | CIN NO. L35911DL1984PLC017354 • Visit www.heromotocorp.com

www.readwhere.com